Compare
Protara Therapeutics, Inc. vs Instil Bio, Inc. vs Metagenomi Therapeutics, Inc. vs enGene Therapeutics Inc.
| Latest fiscal year | Protara Therapeutics, Inc. TARA | Instil Bio, Inc. TIL | Metagenomi Therapeutics, Inc. MGX | enGene Therapeutics Inc. ENGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-10-31 |
| Revenue | n/a | n/a | $25.21M | n/a |
| Revenue growth (YoY) | n/a | n/a | -51.8% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | -380.9% | n/a |
| Net margin | n/a | n/a | -348.5% | n/a |
| Net income | -$57.44M | -$71.37M | -$87.87M | -$117.30M |
| EPS (Diluted) | -$1.34 | -$10.70 | -$2.36 | $2.29 |
| Operating cash flow | -$56.37M | -$36.62M | -$88.89M | -$99.24M |
| Free cash flow | -$56.46M | n/a | -$89.47M | -$100.72M |
| Cash & equivalents | $49.66M | $6.64M | $41.72M | $50.15M |
| Total assets | $209.47M | $203.52M | $221.10M | $221.47M |
| Total liabilities | $13.06M | $89.66M | $62.51M | $53.76M |
| Shareholders' equity | $196.41M | $113.87M | $158.60M | $167.71M |
| Return on year-end equity | -29.2% | -62.7% | -55.4% | -69.9% |
| Shares outstanding | 53.59M | 6.78M | 37.62M | 52.02M |
Revenue, most recent five fiscal years
| Fiscal year | Protara Therapeutics, Inc. | Instil Bio, Inc. | Metagenomi Therapeutics, Inc. | enGene Therapeutics Inc. |
|---|---|---|---|---|
| Latest | $2.95M Ended 2014-12-31 | $0 Ended 2021-12-31 | $25.21M Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | $138.0K Ended 2020-12-31 | $52.30M Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | n/a | $44.76M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | n/a | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |